{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:10:49Z","timestamp":1790964649212,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Wilson disease (WD) treatment aims to reduce copper accumulation in the liver and brain. Zinc salts (ZS) are often associated with gastrointestinal side effects, poor adherence, and reduced efficacy. Copper chelators, such as trientine tetrahydrochloride (TETA4), offer an alternative for patients who are intolerant or unresponsive to ZS. This observational study assesses the long-term efficacy and safety of switching from ZS to TETA4 in twenty WD patients (15 hepatic, 5 hepato-neurological) from the French WD Registry. Treatment goals included normalization of aminotransferases, stabilization or improvement of the liver (APRI, liver stiffness and liver ultrasonography; US) and the neurological (Unified Wilson\u2019s Disease Rating Scale; UWDRS) involvement, Clinical Global Impression (CGI) severity scale, and achievement of copper balance targets. Assessments were performed at baseline and every 6\u2009months for 3\u2009years. Adverse events were recorded throughout the follow-up. The results revealed that the main reasons for switching were gastrointestinal intolerance and loss of efficacy with ZS; 60% had elevated ALT at baseline. TETA4 was initiated at a median dose of 412.5\u2009mg (360\u2013450) and titrated up to 750\u2009mg\/day (600\u2013900\u2009mg) to achieve the treatment goals. Over 3\u2009years, no changes were observed in ALT, APRI, liver US, UWDRS and CGI scores. TETA4 was well tolerated. In conclusion, transitioning from ZS to TETA4 maintained clinical stability and adherence with a favorable safety profile. Dose adjustments suggest conversion ratios of ~1:6 elemental zinc.<\/jats:p>","DOI":"10.1186\/s13023-026-04311-8","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:53:29Z","timestamp":1775206409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transition from zinc salts to trientine tetrahydrochloride in a cohort of adult patients with Wilson disease: the ZICUP study"],"prefix":"10.1186","volume":"21","author":[{"given":"Aur\u00e9lia","family":"Poujois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickael Alexandre","family":"Obadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouzha","family":"Oussedik-Djebrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Couchonnal-Bedoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Ory-Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0345-963X","authenticated-orcid":false,"given":"Dominique","family":"Debray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,3]]},"reference":[{"issue":"Suppl 2","key":"4311_CR1","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.21037\/atm.2019.02.48","volume":"7","author":"I Mohr","year":"2019","unstructured":"Mohr I, Weiss KH. Current anti-copper therapies in management of Wilson disease. Ann Transl Med. 2019;7(Suppl 2):S69","journal-title":"Ann Transl Med"},{"issue":"6","key":"4311_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.clinre.2018.03.007","volume":"42","author":"A Poujois","year":"2018","unstructured":"Poujois A, Woimant F. Wilson\u2019s disease: a 2017 update. Clin Res Hepatol Gastroenterol. 2018;42(6):512\u201320","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"11","key":"4311_CR3","doi-asserted-by":"publisher","first-page":"e15646","DOI":"10.1111\/ene.15646","volume":"31","author":"A Czlonkowska","year":"2024","unstructured":"Czlonkowska A, Niewada M, Litwin T, et al. Seven decades of clinical experience with Wilson\u2019s disease: report from the national reference centre in Poland. Eur J Neurol. 2024;31(11):e15646","journal-title":"Eur J Neurol"},{"key":"4311_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/nyas.12437","volume":"1315","author":"KH Weiss","year":"2014","unstructured":"Weiss KH, Stremmel W. Clinical considerations for an effective medical therapy in Wilson\u2019s disease. Ann N Y Acad Sci. 2014;1315:81\u201385","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"4311_CR5","doi-asserted-by":"publisher","first-page":"1028\u20131035 e1021","DOI":"10.1016\/j.cgh.2013.03.012","volume":"11","author":"KH Weiss","year":"2013","unstructured":"Weiss KH, Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol. 2013;11(8):1028\u20131035 e1021\u20131022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4311_CR6","doi-asserted-by":"crossref","unstructured":"Hefter H, Kruschel TS, Novak M, et al. Differences in the time course of recovery from brain and liver dysfunction in conventional long-term treatment of Wilson disease. J Clin Med. 2023;12(14)","DOI":"10.3390\/jcm12144861"},{"issue":"4","key":"4311_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.cgh.2013.11.009","volume":"12","author":"ML Schilsky","year":"2014","unstructured":"Schilsky ML. Long-term outcome for Wilson disease: 85% good. Clin Gastroenterol Hepatol. 2014;12(4):690\u201391","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4311_CR8","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, et al. EASL-ERN clinical practice guidelines on Wilson\u2019s disease. J Hepatol. 2025;82:690\u2013728","DOI":"10.1016\/j.jhep.2024.11.007"},{"issue":"6","key":"4311_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/MPG.0000000000000926","volume":"61","author":"R Santiago","year":"2015","unstructured":"Santiago R, Gottrand F, Debray D, et al. Zinc therapy for Wilson disease in children in French pediatric centers. J Pediatr Gastroenterol Nutr. 2015;61(6):613\u201318","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"4311_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13023-024-03271-1","volume":"19","author":"EJ Lee","year":"2024","unstructured":"Lee EJ, Woo MH, Moon JS, Ko JS. Efficacy and safety of D-penicillamine, trientine, and zinc in pediatric Wilson disease patients. Orphanet J Rare Dis. 2024;19(1):261","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"4311_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep4.1384","volume":"3","author":"MA Camarata","year":"2019","unstructured":"Camarata MA, Ala A, Schilsky ML. Zinc maintenance therapy for Wilson disease: a comparison between zinc acetate and alternative zinc preparations. Hepatol Commun. 2019;3(8):1151\u201358","journal-title":"Hepatol Commun"},{"issue":"2","key":"4311_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.33590\/emj\/FUMO2589","volume":"9","author":"HP Di Dato F","year":"2024","unstructured":"Di Dato F HP. Zinc for Wilson\u2019s disease: what we know and what we don\u2019t Know. EMJ. 2024;9(2):84\u201395","journal-title":"EMJ"},{"issue":"3","key":"4311_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.lab.2005.01.007","volume":"145","author":"M Marcellini","year":"2005","unstructured":"Marcellini M, Di Ciommo V, Callea F, et al. Treatment of Wilson\u2019s disease with zinc from the time of diagnosis in pediatric patients: a single-hospital, 10-year follow-up study. J Lab Clin Med. 2005;145(3):139\u201343","journal-title":"J Lab Clin Med"},{"issue":"5","key":"4311_CR14","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/HEP.0000000000000708","volume":"79","author":"FT Kirk","year":"2024","unstructured":"Kirk FT, Munk DE, Swenson ES, et al. Effects of trientine and penicillamine on intestinal copper uptake: a mechanistic 64 Cu PET\/CT study in healthy humans. Hepatology. 2024;79(5):1065\u201374","journal-title":"Hepatology"},{"issue":"12","key":"4311_CR15","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S2468-1253(22)00270-9","volume":"7","author":"ML Schilsky","year":"2022","unstructured":"Schilsky ML, Czlonkowska A, Zuin M, et al. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(12):1092\u2013102","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4311_CR16","doi-asserted-by":"crossref","unstructured":"Woimant F, Debray D, Morvan E, Obadia MA, Poujois A. Efficacy and safety of two salts of trientine in the treatment of Wilson\u2019s disease. J Clin Med. 2022;11(14)","DOI":"10.3390\/jcm11143975"},{"key":"4311_CR17","unstructured":"PNDS. Protocole National de Diagnostic et de Soins. 2021. https:\/\/www.has-santefr\/upload\/docs\/application\/pdf\/2021-11\/pnds_wilson_texte_8nov21.pdf"},{"key":"4311_CR18","unstructured":"Cuprior. Summary of product characteristics. https:\/\/www.emaeuropaeu\/en\/documents\/product-information\/cuprior-epar-product-information_en.pdf"},{"issue":"1","key":"4311_CR19","first-page":"1","volume":"41","author":"A Czlonkowska","year":"2007","unstructured":"Czlonkowska A, Tarnacka B, Moller JC, et al. Unified Wilson\u2019s disease rating scale - a proposal for the neurological scoring of Wilson\u2019s disease patients. Neurol Neurochir Pol. 2007;41(1):1\u201312","journal-title":"Neurol Neurochir Pol"},{"issue":"7","key":"4311_CR20","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337","journal-title":"Psychiatry (Edgmont)"},{"issue":"5","key":"4311_CR21","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s00216-009-2809-6","volume":"394","author":"S El Balkhi","year":"2009","unstructured":"El Balkhi S, Poupon J, Trocello JM, et al. Determination of ultrafiltrable and exchangeable copper in plasma: stability and reference values in healthy subjects. Anal Bioanal Chem. 2009;394(5):1477\u201384","journal-title":"Anal Bioanal Chem"},{"issue":"6","key":"4311_CR22","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/jimd.12430","volume":"44","author":"E Jacquelet","year":"2021","unstructured":"Jacquelet E, Poujois A, Pheulpin MC, et al. Adherence to treatment, a challenge even in treatable metabolic rare diseases: a cross sectional study of Wilson\u2019s disease. J Inherit Metab Dis. 2021;44(6):1481\u201388","journal-title":"J Inherit Metab Dis"},{"key":"4311_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1750-1172-9-41","volume":"9","author":"G Ranucci","year":"2014","unstructured":"Ranucci G, Di Dato F, Spagnuolo MI, Vajro P, Iorio R. Zinc monotherapy is effective in Wilson\u2019s disease patients with mild liver disease diagnosed in childhood: a retrospective study. Orphanet J Rare Dis. 2014;9:41","journal-title":"Orphanet J Rare Dis"},{"key":"4311_CR24","doi-asserted-by":"crossref","unstructured":"Avan A, Czlonkowska A, Gaskin S, Granzotto A, Sensi SL, Hoogenraad TU. The role of zinc in the treatment of Wilson\u2019s disease. Int J Mol Sci. 2022;23(16)","DOI":"10.3390\/ijms23169316"},{"issue":"5","key":"4311_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s13318-021-00704-1","volume":"46","author":"KH Weiss","year":"2021","unstructured":"Weiss KH, Thompson C, Dogterom P, et al. Comparison of the pharmacokinetic profiles of trientine tetrahydrochloride and trientine dihydrochloride in healthy subjects. Eur J Drug Metab Pharmacokinet. 2021;46(5):665\u201375","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"4311_CR26","doi-asserted-by":"publisher","first-page":"e12822","DOI":"10.1002\/jimd.12822","volume":"48","author":"S Fang","year":"2025","unstructured":"Fang S, Furegato M, Azzi J, Couchonnal-Bedoya E, Debray D. Epidemiology and economic burden of Wilson disease in France: a nationwide population-based study. J Inherit Metab Dis. 2025;48(1):e12822","journal-title":"J Inherit Metab Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04311-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04311-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04311-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:27:21Z","timestamp":1781645241000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04311-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4311"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04311-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,3]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB00003888, IORG0003254, FWA00005831) of the French Institute of Medical research and Health, and by the local ethics committee of the Rothschild Foundation Hospital (Paris, France), and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients included in the French WD Registry","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have read the journal\u2019s policy on disclosure of potential conflicts of interest. Aurelia Poujois has received consulting and speaker fees from Orphalan, Alexion, Merz, Curatis and Univar and institutional grants from Orphalan, Alexion, Merz and AddMedica. Nouzha Djebrani-Oussedik has received consulting and speaker fees from Orphalan and Alexion. Dominique Debray has received consulting and speaker fees from Orphalan and Alexion. Micka\u00ebl Alexandre Obadia has received consulting and speaker fees from Orphalan. Eduardo Couchonnal-Bedoya has received consulting and speaker fees from Orphalan, Univar, Vivet and Alexion. Fabienne Ory-Magne has received consulting and speaker fees from Orphalan","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}